Should I buy Medtronic stock in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking Medtronic's performance for over three years. Every month, over a million users in the US trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes only and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Medtronic.

What is Medtronic?

The Medtronic Stock Price

The price of Medtronic stock is rising this week. MDT trades at $88.60, with a 24-hour gain of $0.32 (+0.36%) and an increase of 2.80% over the past week. The company’s market capitalization is $113.11 billion, average daily volume is 8.06 million shares, and the P/E ratio stands at 24.45. Medtronic offers a dividend yield of 3.26% and a beta of 0.81, reflecting moderate volatility. This strong performance and steady income potential make Medtronic an attractive option for US investors seeking stability.

Our full analysis of Medtronic stock

After an in-depth review of Medtronic’s latest financial achievements and three-year stock performance, we have harnessed a combination of proprietary algorithms, robust financial indicators, real-time technical signals, industry-wide market data, and peer benchmarking to provide actionable insight. Synthesizing these inputs has enabled us to form a holistic view of the company’s strengths and future trajectory. So, why might Medtronic stock once again become a strategic entry point into the medical technology sector in 2025?

Recent performance and market context

Medtronic’s stock has demonstrated a clear resurgence over the past year, closing recently at $88.60, up 14.8% year-over-year and gaining 2.8% in just the last week. This revival comes amid a broader sectoral shift favoring innovative medtech leaders that have robust fundamentals and a global reach. Positive quarterly results have reignited market optimism after a phase of consolidation, further buoyed by Medtronic’s proactive investor communications and steady dividend payments. The supportive macroeconomic backdrop—in particular rising healthcare spending, demographic tailwinds from an aging population, and regulatory tailwinds for next-generation medical devices in the US—continue to cultivate a fertile environment for Medtronic’s expansion. Notably, analyst consensus places a medium-term price target at $96.58, underscoring confidence in the company’s progression and aligning with the current upward momentum.

Technical analysis

From a technical standpoint, Medtronic currently delivers a compelling short- and medium-term profile. The Relative Strength Index (RSI) registers at 61.65, positioning the stock comfortably in bullish territory, yet not overbought—an ideal zone for tactical entries. The MACD remains positive at 0.46, supplying further evidence of upward price momentum with no sign of exhaustion. Robust support is established around $81.04, with successive tests over the year reinforcing its strength, while the primary resistance at $96.34 offers a distinct upside target. Notably, Medtronic is trading above all relevant moving averages—20, 50, 100, and 200 days—each signaling a ‘Buy’ condition, and its “Strong Buy” composite technical rating (12 buy signals, 0 sell) points to the likelihood of continued accretive moves. This convergence of signals paints a picture of favorable technical momentum and a well-defined risk/reward setup, especially as broader sentiment towards the sector remains constructive.

Fundamental analysis

Delving deeper, Medtronic’s fundamental profile is increasingly attractive. In fiscal 2025, the company reported $33.54 billion in annual revenue, reflecting 3.6% reported—and an impressive 4.9% organic—growth. Profitability remains strong, with an EBITDA of $9.11 billion and net income of $4.66 billion, driving EPS to $3.61. These advances outpaced analyst expectations and reinforced Medtronic’s reputation for operational excellence. Importantly, the company’s 24.45 P/E ratio remains notably justified for a global market leader enrolled in a growth phase—especially given its dividend yield of 3.26%, above the sector average and consistently increased over recent years. Medtronic’s diversified portfolio across cardiovascular, neuroscience, surgical, and diabetes technologies, combined with deep investments in R&D and strategic partnerships, underpin sustainable competitive advantages and long-term brand strength. Its response to regulatory and competitive pressures has been notably agile—reinforcing its status as an innovation-driven, future-ready medtech powerhouse.

Volume and liquidity

Medtronic’s liquidity profile further supports its investment appeal. Average daily trading volume exceeds 8 million shares—indicative of robust institutional and retail interest as well as rapid order execution and efficient price discovery. The substantial free float, making up virtually all shares outstanding, adds dynamism to valuation, limiting the risk of liquidity-driven volatility. Moreover, the company enjoys 86.84% institutional ownership—a strong endorsement of confidence from leading asset managers and pension funds, and a signal that professional investors continue to find the name attractive at current valuations.

Catalysts and positive outlook

Looking ahead, several potential catalysts bolster the bullish thesis. Medtronic is moving forward with the spin-off of its Diabetes segment as a stand-alone public entity (“MiniMed”), which could unlock significant shareholder value by focusing capital and R&D on segments with the highest growth potential. The firm’s strategic partnership with Abbott to co-develop an integrated continuous glucose monitoring (CGM) system is another growth lever, reinforcing Medtronic’s leadership in digital and AI-enhanced medical devices. Recent FDA approvals—such as MiniMed 780G and Simplera Sync technologies—not only validate innovation but also expand the addressable market in diabetes care in the US and globally. In addition, Medtronic’s robust ESG strategy, emphasis on quality-of-life-enhancing solutions, and a regular quarterly dividend (with a recent increase announced for July 2025) make the company a top candidate for inclusion in both growth and income portfolios.

On a macro level, the sector is buoyed by long-term consumption trends such as increasing healthcare expenditures, technological adoption in precision medicine, and accelerating demand for advanced disease management solutions. Medtronic is well-positioned to benefit from continued regulatory support for innovation, demographic shifts, and expanding healthcare access both in the US and internationally.

Investment strategies

For short-term traders, Medtronic’s current technical structure—trading above key moving averages, with bullish momentum and well-defined support around $81—offers a favorable entry for those targeting imminent catalysts or earnings-driven moves. Swing and medium-term investors may see the ongoing rebound from recent lows and the anticipated benefits of the Diabetes spin-off as attractive points of inflection. For long-term investors, Medtronic’s industry leadership, diversified revenue streams, history of dividend growth, and commitment to breakthrough innovation all combine to create a sound foundation for compounding capital over time.

• Short-term: Tactical entry above support, targeting next resistance (~$96), monitoring momentum and news on segment separations or regulatory breakthroughs.
• Medium-term: Positioning ahead of MiniMed’s separation, tracking implementation of new partnerships and product launches, and following earnings upgrades or guidance increases.
• Long-term: Capitalizing on global healthcare trends, innovation cycles, Medtronic’s entrenched moat, and reliable dividend stream for wealth accumulation.

Is it the right time to buy Medtronic?

In summary, Medtronic distinguishes itself with a unique combination of innovation, scale, financial resilience, and shareholder alignment. The ongoing stock price recovery, consensus-beating earnings, and imminent value-generating events like the Diabetes business spin-off set the stage for an extended bullish phase. Continuous R&D leadership, increased dividend payouts, and partnership initiatives further reinforce the company’s growth trajectory. While every investor should assess their own risk tolerance and portfolio needs, Medtronic, at its current valuation and technical setup, seems to represent an excellent opportunity for those seeking exposure to a premier medtech leader with both defensive qualities and strong upside potential.

Medtronic’s resilient fundamentals, clear technical upside, and robust pipeline of strategic catalysts together suggest that the stock may be entering a new bullish phase, deserving of serious consideration by any investor focused on the future of healthcare technology.

How to Buy Medtronic Stock in the US

Buying Medtronic stock online is simple and secure when you use a regulated broker in the United States. Investors typically choose between two main methods: a spot, or “cash,” purchase of Medtronic shares, or trading via Contracts for Difference (CFDs), which offers leveraged access to price movements. Both routes can be completed quickly from your phone or computer. Be sure to consult the broker comparison available further down this page to find the platform best suited to your needs.

Spot buying

A cash purchase means you become a direct owner of Medtronic shares, held in your brokerage account. Most US brokers charge a low, fixed fee per order—often around $5 per trade. This approach is transparent and ideal for long-term investors.

Gain scenario

If the Medtronic share price is $88.60, you can buy around 11 shares with a $1,000 stake, including a brokerage fee of around $5.

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFDs (Contracts for Difference) allow you to speculate on Medtronic stock price movements without owning the actual shares. Fees usually include a spread (the difference between buy and sell prices) and overnight financing if you hold leveraged positions beyond a day. CFDs offer the flexibility of leverage, but also come with higher risk.

Gain scenario

You open a CFD position on Medtronic shares, with 5x leverage.

This gives you a market exposure of $5,000.

If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before investing, always compare brokers’ fees, trading conditions, and available tools. Your choice between spot buying and CFDs should depend on your investment goals and risk tolerance. For detailed comparisons, refer to the broker overview further down this page.

Our 7 Tips for Buying Medtronic Stock

The latest news about Medtronic

Medtronic stock advances by 2.80% this week, confirming continued positive momentum on the NYSE. The share price has risen notably over the past seven days, outperforming the broader market thanks to strong technical indicators and robust investor interest, a reflection of sustained confidence among US institutional and retail investors.

Medtronic confirms strong technical “Buy” signals with all key moving averages pointing upward. As of July 3, 2025, the 20-, 50-, 100-, and 200-day moving averages all signal further upside for the stock. This rare technical alignment, coupled with an RSI of 61.65 and MACD in positive territory, identifies Medtronic as a strong candidate for continued price appreciation in the US market.

Recent FDA approvals bolster Medtronic’s US diabetes segment and innovation profile. Several of Medtronic’s new products—such as the MiniMed 780G insulin system and InPen app—have received positive US regulatory decisions in the past few days, enhancing the company’s competitive advantage in its largest consumer market and driving forward-looking sentiment.

Medtronic’s annual dividend policy remains solid, with the next payment scheduled for July 11, 2025. Shareholders benefit from a $2.84 annual dividend per share, representing a yield of 3.26%. The recent increase in quarterly dividends demonstrates management’s ongoing commitment to return value to US-based investors.

Medtronic’s US operational hub in Minnesota drives domestic R&D and employment. The company’s Minneapolis-anchored presence underpins its leadership in medical device technology, providing strategic access to North American regulatory agencies, healthcare systems, and talent—factors expected to continue supporting growth and innovation for US markets.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.